FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company (NYSE: LLY) announced today. “Since generalized anxiety disorder can be a chronic illness, it is important that doctors and their patients find a treatment option that is effective in both the… Read More »